Tag Archives: muscarinic antagonist

AstraZeneca completes the transfer of Eklira/Tudorza and Duaklir global rights to Covis Pharma Group for $270 million

(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release